Orexo AB: Abstral(R) Launched and Now Available in the United States  
4/4/2011 9:17:20 AM

UPPSALA, Sweden--(BUSINESS WIRE)-- Orexo AB (STO:ORX) announces today that its partner ProStrakan Group plc (LSE:PSK) has launched Abstral in the United States. Abstral, which is the only fast-acting sublingual tablet for the treatment of breakthrough cancer pain, is now available to patients in the US. In 2010 the market value for fast-acting fentanyl products was $530m. (Source: Wolter Kluwers).